Cardano Risk Management B.V. Lowers Position in Merck & Co., Inc. $MRK

Cardano Risk Management B.V. cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 89.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 979,681 shares of the company’s stock after selling 8,639,639 shares during the quarter. Merck & Co., Inc. makes up approximately 1.2% of Cardano Risk Management B.V.’s holdings, making the stock its 23rd biggest position. Cardano Risk Management B.V.’s holdings in Merck & Co., Inc. were worth $117,845,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Chesapeake Wealth Management increased its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the last quarter. South Plains Financial Inc. increased its stake in Merck & Co., Inc. by 0.6% during the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after acquiring an additional 89 shares during the last quarter. Syverson Strege & Co lifted its position in Merck & Co., Inc. by 2.2% in the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after buying an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV raised its stake in shares of Merck & Co., Inc. by 0.4% in the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after acquiring an additional 91 shares during the period. Finally, Westside Investment Management Inc. boosted its position in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after buying an additional 93 shares during the period. 76.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on MRK shares. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.72.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $125.36 on Friday. The firm has a market capitalization of $309.61 billion, a P/E ratio of 35.31, a P/E/G ratio of 2.71 and a beta of 0.21. The company’s fifty day moving average price is $115.88 and its 200 day moving average price is $114.23. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.96.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved Keytruda plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer, expanding Merck’s oncology franchise in Europe. European Commission Approves KEYTRUDA Plus Padcev
• Positive Sentiment: The FDA approved Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1-positive advanced triple-negative breast cancer, adding another growth opportunity for the drug. FDA Approves Keytruda and Trodelvy for TNBC
• Positive Sentiment: Analyst commentary has also been supportive, with CICC Research initiating coverage at outperform and a price target above the recent trading range, reinforcing bullish sentiment around the stock. Merck Coverage Update
• Neutral Sentiment: Other reports noted that competitor Gilead won EC approval to expand Trodelvy’s label in metastatic TNBC, which is relevant to Merck because Trodelvy is part of the newly approved Keytruda combination, but the net market impact is still unclear. Gilead Wins EC Approval to Expand Trodelvy’s Label
• Neutral Sentiment: Several analyst notes were mixed, including Citi’s hold rating and Scotiabank’s buy rating, suggesting the latest move is being driven more by product news than by a major change in analyst consensus. Citi Keeps Their Hold Rating on Merck & Company

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.